

1 **Real-World Effectiveness of Live Attenuated vs. Inactivated Influenza Vaccines in Children**

2 Vera Rigamonti (MSc)¹, Vittorio Torri (MSc)², Shaun K Morris (MD, MPH, FRCPC, Prof)^{3,4,5,6},
3 Francesca Ieva (Prof)^{2,7}, Carlo Giaquinto (Prof)⁸, Daniele Donà (MD, PhD)⁸, Costanza Di Chiara
4 (MD, PhD)^{1,3,8*}, Anna Cantarutti (PhD)^{1*} on behalf of the CARICE study group

5

6 *contributed as co-senior authors

7 A complete list of CARICE study group members appears in Appendix 1

8

9 **Affiliations:**

10 1 Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistic and
11 Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of
12 Milano-Bicocca, Milano, Italy

13 2 MOX – Modelling and Scientific Computing Lab, Department of Mathematics, Politecnico di
14 Milano, Milano, Italy

15 3 Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada

16 4 Center for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada

17 5 Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

18 6 Division of Clinical Public Health and Centre for Vaccine Preventable Diseases, Dalla Lana
19 School of Public Health, Toronto, ON, Canada

20 7 HDS - Health Data Science Centre, Human Technopole, Milano, Italy

21 8 Department of Women's and Children's Health, University of Padova, Padova, Italy

22

23 **Address correspondence to:** Costanza Di Chiara MD, Division of Pediatric Infectious Diseases,
24 Department for Women's and Children's Health, University of Padua, Italy. Via Giustiniani 3,
25 Padua, Italy. Contact: Phone: 0498213585, E-mail: costanza.dichiara@phd.unipd.it

26

27 **Short title:** Live Attenuated Influenza Vaccine Effectiveness

28

29 **Conflict of Interest Disclosures (includes financial disclosures):** The authors have indicated that
30 they have neither potential conflicts of interest nor financial relationships relevant to the article to
31 disclose.

32

33 **Funding/Support:** This work is partially supported by CARICE (COVID-19 and Acute
34 Respiratory Infections: the Clinical and Epidemiological changes in the pediatric population)
35 project, which is funded by the Ministry of University and Research within the PRIN 2022 PNRR.

36

37 **Abbreviations:**

38 IIV, inactivated influenza vaccine
39 LAIV, live attenuated influenza vaccine
40 quadrivalent LAIV (LAIV-4)
41 ILI, influenza-like illness
42 FP, family pediatrician
43 VE, vaccine effectiveness
44 HR, hazard ratio
45 CI, confidence interval
46 PPIP, special professional commitment service

47

48 **Article Summary:** A retrospective population-based cohort analysis showing moderate
49 effectiveness of live attenuated influenza vaccines (LAIVs) in preventing influenza/influenza-like-
50 illness in Italian children.

51

52 **What's Known on This Subject**

53 There is conflicting evidence on the effectiveness of the quadrivalent live attenuated influenza
54 vaccine LAIV (LAIV-4) in the pediatric population.

55

56 **What This Study Adds**

57 This population-based study assesses the effectiveness of LAIVs against influenza/influenza-like
58 illness (ILI) among children in Italy in the post-COVID-19 influenza seasons using real-world data.
59 Our findings document moderate protection provided by LAIVs against influenza/ILI in the 2022-
60 2023 and 2023-2024 seasons.

61

62

63 **Contributors Statement Page**

64 Dr. Vera Rigamonti performed the statistical analysis, interpreted the results, and drafted the initial
65 manuscript;

66 Dr. Vittorio Torri conceptualized and designed the artificial intelligence algorithms;

67 Dr. Daniele Donà contributed to data interpretation;

68 Drs Anna Cantarutti and Costanza Di Chiara, designed the study, contributed to the analysis plan,
69 interpreted the results, supervised the project, and contributed to the manuscript writing;

70 Profs. Shaun K Morris, Francesca Ieva, and Carlo Giaquinto interpreted the results and critically
71 reviewed the manuscript for important intellectual content.

72 All authors reviewed, edited, and approved the final version of the manuscript, authorized its
73 submission for publication, and agree to be accountable for all aspects of the work.

74 **Abstract (word count=249/250)**

75 **Background and objectives:** Quadrivalent live attenuated influenza vaccines (LAIV-4) offer an
76 alternative to inactivated influenza vaccines (IIV) for children aged 2-17 years, but data on their
77 comparative effectiveness are limited. This study assessed vaccination rates and real-world
78 effectiveness of LAIV-4 and IIV in preventing influenza and influenza-like illness (ILI) in Italian
79 children during the 2022-2023 and 2023-2024 seasons.

80 **Methods:** We conducted a population-based cohort study of children aged 2-14 years from
81 September 2022 to April 2024, using data from Pedianet, a pediatric primary care database of
82 anonymized records from family pediatricians. Children vaccinated with LAIV-4 or IIV were
83 compared to unvaccinated children. The primary outcome was any first influenza or ILI episode.
84 Monthly vaccination incidence rates per 1,000 person-months were calculated for each vaccine
85 type. Hazard ratios (HRs) and their 95% confidence intervals (CIs) for vaccine effectiveness (VE)
86 were estimated using adjusted mixed-effects Cox models.

87 **Results:** A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children
88 were included for the 2022-2023 and 2023-2024 seasons, respectively. Vaccination rates were
89 12.71 and 12.85 per 1,000 person-months, respectively. Compared to unvaccinated children, LAIV-
90 4 had an overall effectiveness of 43% (95% CI, 32%-53%), while IIV effectiveness was 54% (95%
91 CI, 46%-61%). In 2022-2023, LAIV-4 (38% [95% CI, 12%-56%]) and IIV (49% [95% CI, 37%-
92 58%]) had comparable effectiveness. In 2023-2024, LAIV-4 (40% [95% CI, 25%-52%]) was
93 slightly less effective than IIV (58% [95% CI, 44%-68%])(p=0.048).

94 **Conclusions:** An overall moderate, comparable effectiveness of LAIV-4 and IIV in preventing
95 influenza/ILI among Italian children was observed.

96

97 **Keywords:** influenza, influenza vaccine, vaccine effectiveness, real-world data, population-based
98 study, children

99

100 **WORD count: 2593**

101 **Background**

102 Influenza causes seasonal epidemics and occasional pandemics, leading to significant
103 morbidity and mortality worldwide [1]. While children and adolescents generally face a lower risk
104 of severe illness compared to infants and the elderly [2], they remain vulnerable to severe infections
105 [3-5]. Moreover, they play a crucial role in the spread of the virus in the communities [3-8].

106 Vaccination is the most cost-effective strategy to prevent seasonal influenza, reducing
107 morbidity and reducing community transmission, thus protecting vulnerable groups [9,10].
108 However, the prevalence of children vaccinated against influenza remains low and, in Italy, ranged
109 from 7% to 15% during the flu seasons from 2009 to 2018 [10].

110 Inactivated influenza vaccines (IIV) have been the cornerstone of influenza prevention for decades.
111 Live attenuated influenza vaccines (LAIV), administered as a nasal spray, have only recently started
112 being extensively used as an alternative to intramuscular IIV for children aged 2-17 years. Both
113 vaccines are currently quadrivalent and updated annually based on national and international
114 recommendations [11].

115 In Italy, influenza vaccination is offered free of charge to all children aged six months to six years,
116 although it is recommended for all pediatric age groups [12]. Two-dose influenza vaccination is
117 recommended in children younger than nine years who haven't received previous influenza
118 vaccinations, regardless of the type of vaccine (LAIV or IIV); one-dose influenza vaccination is
119 recommended for other children [12].

120 The immune responses elicited by these two vaccine types differ significantly, potentially
121 impacting their effectiveness [13]. IIVs induce strong serum antibody responses, particularly IgG,
122 but have limited capacity to induce mucosal IgA or T-cell responses. Conversely, LAIVs elicit a
123 broader immune response, encompassing cellular, humoral, and mucosal components [14]. This
124 broader response better mimics natural infection and may offer enhanced protection against a wider
125 range of influenza strains, including those not closely matched to the vaccine, as well as reducing
126 transmission [14].

127 Studies on the effectiveness of LAIV and IIV in children show inconsistent results [15-18].
128 Some comparative studies suggest superior efficacy of LAIV over IIV [3,19-21]. However,
129 observational studies indicate mixed effectiveness of LAIVs depending on the setting and
130 circulating strain [22-25].

131 This population-based cohort study aimed to describe the administration rate of LAIV-4 and
132 IIV and assess the real-world effectiveness of LAIV-4 vs IIV in preventing influenza and influenza-
133 like illness (ILI) episodes among Italian children and adolescents during the 2022-2023 and 2023-
134 2024 influenza seasons when LAIV-4 became available in Italy.

135

136 ***Materials and Methods***

137 *Setting*

138 Publicly funded primary healthcare services for children in Italy are delivered free of charge
139 by individual Family Pediatricians (FPs) within the National Health System. This study utilized
140 data from Pedianet (<http://www.pedianet.it>), a well-established electronic health record database
141 specifically designed for pediatric care covering around 4% of the annual pediatric population [26].
142 Pedianet encompasses data from over 200 FPs across Italy who utilize the Junior Bit® software in
143 their practices, providing a representative coverage of the Italian pediatric population [26].

144 This comprehensive database includes anonymized patient-level information, including
145 demographics, growth parameters, diagnoses and symptoms (both ICD-9-CM coded and free text
146 entries), medication prescriptions, and disease-based healthcare exemptions — which cover the
147 costs of essential medical services such as diagnostics, treatments, and medications required for
148 managing chronic conditions— and vaccination history.

149 In Italy, influenza vaccination is administered by FPs who participate voluntarily in the
150 influenza vaccination program. These FPs receive reimbursement through the Special Professional
151 Commitment Services (PPIPs) registry. Participation in the influenza vaccination program is not

152 mandatory for FPs in Italy. We defined FPs as participants if they vaccinated at least 1.5% of their
153 patients [10].

154 Data anonymization is performed in accordance with Italian regulations. Each anonymized
155 record is assigned a unique numerical identifier. The data is then transmitted monthly to a
156 centralized database located in Padua, Italy, for validation purposes. Inclusion in the Pedianet
157 database is voluntary, and parents/legal guardians must provide general consent for their children's
158 anonymized data to be stored and used for research purposes. The Internal Scientific Committee of
159 Società Servizi Telematici Srl, the legal owner of Pedianet granted ethical approval of the study
160 and access to the database.

161

162 *Study design and study cohort criteria*

163 We conducted a retrospective observational cohort study on children aged 2 to 14 years
164 enrolled in the Pedianet database and followed by FPs adhering to the influenza vaccination
165 program during the observation period from September 1, 2022, to April 30, 2024. We worked on
166 two subsequent flu seasons; the first went from September 1, 2022 to April 30, 2023, and the
167 second from September 1, 2023 to April 30, 2024. To ensure complete data on exposure, outcomes,
168 and covariates, we only included children who adhered to the recommended well-child visit
169 schedule with their FP, aligning with established protocols outlined in previous research [27], and
170 with at least one year of follow-up before entry into the cohort.

171 Children who recorded any influenza/ILI episode from the day of influenza vaccination (day
172 0) to 14 days post-vaccination were excluded.

173

174 *Exposure to influenza vaccine*

175 Children were classified as exposed or unexposed to influenza vaccination for each season
176 included in the study. Exposed children were further classified into those exposed to LAIV-4 and
177 those exposed to IIV, based on whether they received a single dose of each respective vaccine type.

178 Unexposed children were considered the reference group.

179

180 *Outcome and definitions*

181 The primary outcome of the study was any influenza/ILI episode. Only the first seasonal
182 influenza/ILI episode for each child was considered, as repeated influenza episodes within the same
183 season are rare (1.6%), and influenza itself may confer immunity against future infections [28].

184 An influenza/ILI episode was defined based on an artificial intelligence algorithm, which
185 used any reported clinical diagnosis of influenza (ICD-9-CM code: 487, 487.0, 487.1, 487.8),
186 and/or free text of medical charts. A tailored Natural Language Processing algorithm to identify
187 influenza/ILI cases from free text data was defined and validated on manually annotated data. The
188 algorithm analyzed both the free text fields of the Pedianet database and, for patients admitted to
189 hospitals in the Veneto region, the text of their discharge letters. These two sources were found to
190 be complementary in identifying patients with influenza (**Supplementary materials – Description
191 of influenza artificial intelligence algorithms**).

192

193 *Covariates*

194 Covariates used for confounding adjustment included demographic variables (sex, age at the
195 start of each influenza season, Italian region of birth, and deprivation index [29]), influenza
196 vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in
197 the epidemiological season preceding the season of interest, and comorbidities.

198 Children were classified as having comorbidity if they had at least one disease-based
199 healthcare exemption for chronic complex condition (i.e., cystic fibrosis, diabetes, chronic
200 obstructive pulmonary disease, and asthma), immunodeficiency or immunosuppressive therapy,
201 neurological and neurocognitive conditions (including Trisomy 21), prematurity (less than 37 weeks
202 of gestation), renal failure, congenital cardiac disease (including heart failure), or chronic liver
203 conditions (**Supplementary materials – Table S1**).

204

205 *Statistical analysis*

206 Administration rates of influenza vaccination stratified by vaccine type (LAIV-4 or IIV)

207 were calculated per 1,000 person-months.

208 Descriptive statistics were provided, and the chi-squared test was used to assess differences
209 between the groups of children who were unvaccinated, exposed to LAIV-4, and exposed to IIV.

210 Mixed-effect Cox proportional-hazards models were used to assess the effectiveness of
211 LAIV-4 and IIV compared to unexposed children in preventing influenza/ILI, considering the FP as
212 a random effect. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were
213 independently estimated for each vaccine type relative to the unvaccinated group. Vaccine
214 effectiveness (VE) was then calculated as $VE = (1-HR) \times 100$.

215 Influenza vaccine exposure was considered a time-varying covariate to avoid immortal time
216 bias. All models were adjusted for covariates of interest (sex, age at the start of each influenza
217 season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status,
218 number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the
219 epidemiological season preceding the season of interest) and for correlation within children who
220 contributed to more than one influenza season. Follow-up began on September 1st and ended upon
221 death, migration, transfer to an FP outside the Pediatric network, occurrence of the incident
222 outcome, or the end of the study period, which coincided with the end of the season evaluated
223 (April 30).

224 Homogeneity between the LAIV-4 and IIV effectiveness was tested using the chi-squared
225 test [30].

226 Finally, sensitivity analyses were performed stratifying the main models by influenza season
227 and replicating the main analysis on children aged 2-5 years.

228 All data analyses were performed using SAS statistical software, version 14.1 (SAS, College
229 Station, TX, USA). Hypothesis tests were two-sided with a type I error of 0.05.

230

231 **Results**

232 *Study cohort characteristics*

233 A total of 65,545 (472,173 person-months) and 72,377 (527,348 person-months) children
234 were included in the study for the 2022-2023 and 2023-2024 influenza seasons, respectively. The
235 inclusion and exclusion flowchart is shown in **Figure 1**.

236 **Table 1 (Table S2 and S3)** presents the sociodemographic and clinical variables of the
237 study population. Overall, this shows that 125,142 children were unvaccinated, 5,270 were exposed
238 to LAIV-4, and 7,510 were exposed to IIV. Exposed children were younger, mostly born in
239 southern Italy, and had fewer comorbidities. Comparing LAIV-4-exposed and IIV-exposed
240 children, those in the LAIV-4 group were younger and had fewer comorbidities.

241

242 *Influenza vaccine administration rates by season*

243 A total of 6,003 (12.71 per 1,000 person-months) and 6,777 (12.85 per 1,000 person-
244 months) children were vaccinated for influenza in the 2022-2023 and 2023-2024 seasons,
245 respectively.

246 In the 2022-2023 influenza season, LAIV-4 administration rate (3.56 per 1,000 person-months) was
247 lower than that of IIV (9.15 per 1,000 person-months). Interestingly, in the 2023-2024 season, the
248 administration rate of LAIV-4 (6.80 per 1,000 person-months) appeared to converge with that of
249 IIV (6.05 per 1,000 person-months) (**Figure 2**).

250

251 *Effectiveness of LAIV-4 and IIV*

252 **Figure 3** shows the effectiveness of LAIV-4 and IIV against influenza/ILI. Overall,
253 compared to unexposed children, the effectiveness of LAIV-4 was 43% (95% CI, 32%-53%), and

254 the effectiveness of IIV was 54% (95% CI, 46%-61%). There was no significant difference between
255 the effectiveness of LAIV-4 and IIV in preventing influenza/ILI (p-value = 0.095).

256 To better understand the effectiveness of LAIV-4 and IIV against different influenza virus
257 variants, we evaluated the effectiveness of both vaccines against influenza/ILI separately for the
258 2022-2023 and 2023-2024 seasons. In the 2022-2023 season, LAIV-4 (38% [95% CI, 12%-56%])
259 and IIV (49% [95% CI, 37%-58%]) showed comparable effectiveness (p-value = 0.374). However,
260 in the 2023-2024 season, a slightly significantly lower effectiveness of LAIV-4 (40% [95% CI,
261 25%-52%]) compared to IIV (58% [95% CI, 44%-68%]) was observed (p-value = 0.048) (**Figure**
262 **3**).

263 To better evaluate the impact of age on VE, we replicated the main analysis on children
264 aged 2-5 years. The effectiveness of LAIV-4 against influenza/ILI (46% [95% CI, 32%-57%]) was
265 comparable to that of IIV (55% [95% CI, 43%-64%]) (p-value = 0.266).

266

267 *Discussion*

268 This nationwide study aimed to investigate the real-world effectiveness of the LAIV-4 vs
269 IIV among children and adolescents across Italy. To the best of our knowledge, this is the first
270 population-based study assessing the effectiveness of LAIV-4 against influenza/ILI in the Italian
271 pediatric population using real-world data. It is also the first study in Italy to develop a Natural
272 Language Processing algorithm for the identification of patients with influenza/ILI from free text
273 records.

274 Our results strengthen and expand the evidence from other studies evaluating LAIV-4
275 effectiveness in the pediatric population [21,31]. We found moderate protection by LAIV-4 against
276 influenza/ILI episodes, with VE of 38% and 40% in the 2022-2023 and 2023-2024 seasons,
277 respectively. Previous studies evaluated the protection of LAIV-4 against influenza, observing a VE
278 ranging from 0% to 50% in seasons 2014-2015 through 2018-2019 [17,23,24,32]. Our study found
279 similar protection against influenza/ILI in the pediatric population compared to these results.

280 Differences in LAIV-4 effectiveness across studies might be due to several factors, including the
281 age and immune status of recipients and antigenic similarity between the vaccine and circulating
282 strains [21-24,33]. Moreover, differences in influenza VE could also be attributed to varying
283 exposure and outcome definitions among studies [31].

284 We observed similar effectiveness of LAIV-4 and IIV in preventing influenza/ILI in
285 children, in accordance with findings from previous studies [17]. However, a trend emerged when
286 analyzing by influenza season. Although VE was confirmed for both LAIV-4 and IIV in the two
287 study seasons, during the 2023-2024 season, IIV appeared to offer slightly greater protection
288 compared to LAIV-4. Previous analyses have yielded conflicting results due to variations in study
289 populations and influenza strains. While some evidence showed a reduced effectiveness of LAIV
290 compared to IIV against influenza A/H1N1pdm09 in children aged 2 to 17 years during the 2013–
291 2014 and 2015–2016 seasons [14], other research on healthy children aged 6 to 59 months indicated
292 that LAIV were more effective than IIV during the 2004-2005 influenza season [34].

293 The study also documented an increase in LAIV-4 administration rates between the 2022-
294 2023 and 2023-2024 seasons during the implementation of a new type of vaccine in Italy. These
295 results predict a promising higher influenza vaccine uptake among children and adolescents, driven
296 by vaccination campaigns based on less invasive vaccine administration. This aligns with previous
297 research showing caregivers were more likely to accept nasal spray vaccines than injectable ones
298 [35-36].

299 This study has several strengths. The use of data from Pedianet, a large population-based
300 dataset, allowed us to assess the real-world effectiveness of LAIV-4 in Italian children. While
301 randomized clinical trials remain the gold standard for demonstrating vaccine safety and efficacy,
302 real-world evidence has become crucial for ongoing VE monitoring, given the influenza virus's
303 dynamics. Furthermore, due to the Italian-wide coverage of Pedianet, which collects all
304 sociodemographic and clinical information, we obtained complete medical information for enrolled
305 children, thus accounting for the impact of influenza/ILI episodes and influenza vaccination in the

306 previous season. Moreover, the high quality of data on the influenza vaccination provided by FPs
307 adhering to the influenza vaccination program, which reimbursed FPs for every dose of
308 administered influenza vaccine minimizing exposure misclassification.

309 However, this study has several limitations. Children receiving influenza vaccination may
310 differ from unvaccinated children in some unmeasured covariates, which results in residual
311 confounding. The exclusion of children followed by FPs not adhering to the influenza vaccination
312 program could also affect the study. Moreover, Pedianet only includes influenza vaccinations
313 registered by FPs, leading to a small underreporting of vaccine coverage. Additionally, since
314 influenza/ILI cases were defined clinically rather than confirmed by laboratory testing, outcome
315 misclassification cannot be excluded, especially given that in Italy, the 2022–2023 and 2023–2024
316 influenza seasons coincided with similar surges in RSV and COVID-19. Furthermore, due to the
317 lack of hospitalization data, we were unable to assess the effectiveness of IIV and LAIV-4 against
318 hospitalization and severe outcomes, which are the primary goals for vaccinating children. Lastly,
319 the 2022–2024 period was characterized by low pre-existing influenza immunity in the population
320 following the COVID-19 pandemic. While this setting provided a unique opportunity for a more
321 direct assessment of real-world influenza VE, it also raises questions about the generalizability of
322 our findings to seasons with higher pre-existing immunity. However, several studies suggest that
323 pre-existing immunity may not prevent infection but does reduce illness severity [37], supporting
324 that the absence of pre-existing immunity should not significantly affect the generalizability of our
325 results.

326 In conclusion, this population-based analysis provides real-world evidence on the moderate,
327 comparable effectiveness of LAIV-4 and IIV against influenza/ILI among children across Italy.
328 Further studies are needed to confirm our findings in future influenza seasons and investigate the
329 effectiveness of LAIV-4 in preventing severe influenza/ILI in children and adolescents. Research
330 focusing on the effectiveness of the LAIV-4 in the pediatric population is crucial for optimizing

331 pediatric influenza vaccination campaigns to increase vaccination acceptance and uptake among
332 children.

333 *Acknowledgments*

334 The authors thank all the family paediatricians collaborating in Pedianet. Eva Alfieri, Michela
335 Alfiero Bordigato, Angelo Alongi, Biagio Amoroso, Rosaria Ancarola, Barbara Andreola,
336 Giampaolo Anese, Roberta Angelini, Maria Grazia Apostolo, Giovanna Argo, Giovanni Avarello,
337 Lucia Azzoni, Maria Carolina Barbazza, Patrizia Barbieri, Gabriele Belluzzi, Eleonora Benetti,
338 Filippo Biasci, Franca Boe, Stefano Bollettini, Francesco Bonaiuto, Anna Maria Bontempelli,
339 Matteo Bonza, Sara Bozzetto, Andrea Bruna, Ivana Brusaterra, Massimo Caccini, Laura Calì, Sonia
340 Camposilvan, Laura Cantalupi, Luigi Cantarutti, Chiara Cardarelli, Giovanna Carli, Sylvia
341 Carnazza, Massimo Castaldo, Stefano Castelli, Monica Cavedagni, Giuseppe Egidio Cera, Chiara
342 Chillemi, Francesca Cichello, Giuseppe Cicione, Carla Ciscato, Mariangela Clerici Schoeller,
343 Samuele Cocchiola, Giuseppe Collacciani, Valeria Conte, Roberta Corro', Rosaria Costagliola,
344 Nicola Costanzo, Sandra Cozzani, Giancarlo Cuboni, Giorgia Curia, Caterina D'alia, Vito
345 Francesco D'Amanti, Antonio D'Avino, Roberto De Clara, Lorenzo De Giovanni, Annamaria De
346 Marchi, Gigliola Del Ponte, Tiziana Di Giampietro, Giuseppe Di Mauro, Giuseppe Di Santo, Piero
347 Di Saverio, Mattea Dieli, Marco Dolci, Mattia Doria, Dania El Mazloun, Maria Carmen Fadda,
348 Pietro Falco, Mario Fama, Marco Faraci, Maria Immacolata Farina, Tania Favilli, Mariagrazia
349 Federico, Michele Felice, Maurizio Ferraiuolo, Michele Ferretti, Mauro Gabriele Ferretti, Paolo
350 Forcina, Patrizia Foti, Luisa Freo, Ezio Frison, Fabrizio Fusco, Giovanni Gallo, Roberto Gallo,
351 Andrea Galvagno, Alberta Gentili, Pierfrancesco Gentilucci, Giuliana Giampaolo, Francesco
352 Gianfredi, Isabella Giuseppin, Laura Gnesi, Costantino Gobbi, Renza Granzon, Mauro Grelloni,
353 Mirco Grugnetti, Antonina Isca, Urania Elisabetta Lagrasta, Maria Rosaria Letta, Giuseppe Lietti,
354 Cinzia Lista, Ricciardo Lucantonio, Francesco Luise, Enrico Marano, Francesca Marine, Lorenzo
355 Mariniello, Gabriella Marostica, Sergio Masotti, Stefano Meneghetti, Massimo Milani, Stella
356 Vittoria Milone, Donatella Moggia, Angela Maria Monteleone, Pierangela Mussinu, Anna Naccari,
357 Immacolata Naso, Flavia Nicoloso, Cristina Novarini, Laura Maria Olimpi, Riccardo Ongaro, Maria
358 Maddalena Palma, Angela Pasinato, Andrea Passarella, Pasquale Pazzola, Monica Perin, Danilo
359 Perri, Silvana Rosa Pescosolido, Giovanni Petrazzuoli, Giuseppe Petrotto, Patrizia Picco,
360 Ambrogina Pirola, Lorena Pisanello, Daniele Pittarello, Elena Porro, Antonino Puma, Maria Paola
361 Puocci, Andrea Righetti, Rosaria Rizzari, Cristiano Rosafio, Paolo Rosas, Bruno Ruffato, Lucia
362 Ruggieri, Annamaria Ruscitti, Annarita Russo, Pietro Salamone, Daniela Sambugaro, Luigi Saretta,
363 Vittoria Sarno, Valentina Savio, Nico Maria Sciolla, Rossella Semenzato, Paolo Senesi, Carla
364 Silvan, Giorgia Soldà, Valter Spanevello, Sabrina Spedale, Francesco Speranza, Sara Stefani,
365 Francesco Storelli, Paolo Tambaro, Giacomo Toffol, Gabriele Tonelli, Silvia Tulone, Angelo
366 Giuseppe Tummarello, Cristina Vallongo, Sergio Venditti, Maria Grazia Vitale, Concetta Volpe,
367 Francesco Paolo Volpe, Aldo Vozzi, Giulia Zanon, Maria Luisa Zuccolo.

368
369

370

371 **References**

- 372 1. Centers for Disease Control and Prevention. Disease burden of influenza. 2018.
- 373 2. Wang X, Li Y, O'Brien KL, et al. Global burden of respiratory infections associated with
374 seasonal influenza in children under 5 years in 2018: a systematic review and modelling study.
375 *Lancet Glob Health* 2020; 8: e497–510.
- 376 3. Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, et al. Cost
377 effectiveness of influenza vaccine choices in children aged 2–8 years in the U.S. *Am J Prev*
378 *Med.* 2016;50(5):600–8. <https://doi.org/10.1016/j.amepre.2015.12.010>.
- 379 4. Gregg M, Blackhouse G, Loeb M, Goeree R. Economic evaluation of an influenza
380 immunization strategy of healthy children. *Int J Technol Assess Health Care.* 2014;30(4):394–9.
381 <https://doi.org/10.1017/S0266462314000397>.
- 382 5. Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and
383 impact of vaccinating school age children against influenza during a season with circulation of
384 drifted influenza a and B strains, England, 2014/15. *Eurosurveillance.* 2015;20:39.
385 <https://doi.org/10.2807/1560-7917.ES.2015.20.39.30029>.
- 386 6. Grijalva CG, Zhu Y, Simonsen L, Mitchel E, Griffin MR. The Population Impact of a Large
387 School-Based Influenza Vaccination Campaign. Poon LLM, editor. *PLoS One.*
388 2010;5(11):e15097.
- 389 7. King JC. A pilot study of the effectiveness of a school-based influenza vaccination program.
390 *Pediatrics.* 2005;116(6):e868–73. <https://doi.org/10.1542/peds.2005-1301>.
- 391 8. King JC, Lichenstein R, Cummings GE, Magder LS. Impact of influenza vaccination of
392 schoolchildren on medical outcomes among all residents of Maryland. *Vaccine.* 2010
393 Nov;28(49):7737–42. <https://doi.org/10.1016/j.vaccine.2010.09.064>.
- 394 9. Tsang TK, Fang VJ, Ip DKM, et al. Indirect protection from vaccinating children against
395 influenza in households. *Nat Commun* 2019; 10: 106.
- 396 10. Cantarutti A, Barbieri E, Didonè F, Scamarcia A, Giaquinto C, Corrao G. Influenza Vaccination
397 Effectiveness in Paediatric 'Healthy' Patients: A Population-Based Study in Italy. *Vaccines*
398 (Basel). 2022 Apr 10;10(4):582. doi: 10.3390/vaccines10040582.
- 399 11. Centers for Disease Control and Prevention (CDC). Key Facts About Influenza (Flu). Available
400 at: CDC Influenza.
- 401 12. Ministero della salute. Direzione generale della prevenzione sanitaria. Circolare 21 aprile 2023.
402 Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2023-2024. Published
403 on April 21, 2023. Accessed on March 20, 2024. Available at:
404 https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dal
405 [ministero&id=6229](https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dal)
- 406 13. Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza
407 vaccination. *Hum Vaccin Immunother.* 2018 Mar 4;14(3):571-578. doi:
408 10.1080/21645515.2017.1377376. Epub 2018 Jan 3. PMID: 28933664; PMCID: PMC5861782.
- 409 14. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar
410 humoral responses, but only live vaccines induce diverse T-cell responses in young children. *J*
411 *Infect Dis* 2011;204: 845–53.
- 412 15. Chung, J. R., Flannery, B., Ambrose, C. S., Bégué, R. E., Caspard, H., DeMarcus, L., Fowlkes,
413 A. L., Kersellius, G., Steffens, A., Fry, A. M., Influenza Clinical Investigation for Children
414 Study Team, Influenza Incidence Surveillance Project, & US Influenza Vaccine Effectiveness
415 Network (2019). Live Attenuated and Inactivated Influenza Vaccine Effectiveness. *Pediatrics,*
416 143(2), e20182094. <https://doi.org/10.1542/peds.2018-2094>.
- 417 16. Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and
418 inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.
419 *Vaccine.* 2016;34(1):77-82. doi:10.1016/j.vaccine.2015.11.010.

- 420 17. Flannery B. Influenza vaccine effectiveness, including LAIV vs IIV in children and adolescents,
421 US Flu VE Network, 2015-16. [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-05-flannery.pdf)
422 [2016-06/influenza-05-flannery.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-05-flannery.pdf).
- 423 18. Buchan SA, Booth S, Scott AN, et al. Effectiveness of Live Attenuated vs Inactivated Influenza
424 Vaccines in Children During the 2012-2013 Through 2015-2016 Influenza Seasons in Alberta,
425 Canada: A Canadian Immunization Research Network (CIRN) Study. *JAMA Pediatr.*
426 2018;172(9):e181514. doi:10.1001/jamapediatrics.2018.1514.
- 427 19. Minozzi S, Lytras T, Gianola S, et al. Comparative efficacy and safety of vaccines to prevent
428 seasonal influenza: a systematic review and network meta-analysis. *EClinicalMedicine* 2022;46:
429 101331.
- 430 20. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in
431 healthy children. *Cochrane Database Syst Rev* 2018; 2: CD004879.
- 432 21. Shim E, Brown ST, DePasse J, Nowalk MP, Raviotta JM, Smith KJ, et al. Cost effectiveness of
433 influenza vaccine for U.S. children. *Am J Prev Med.* 2016 Sep;51(3):309–17.
434 <https://doi.org/10.1016/j.amepre.2016.02.027>.
- 435 22. Kildegaard H, Lund LC, Pottegård A, Stensballe LG. Effectiveness of the quadrivalent live
436 attenuated influenza vaccine against influenza-related hospitalisations and morbidity among
437 children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial.
438 *Lancet Child Adolesc Health.* 2023 Dec;7(12):852-862. doi: 10.1016/S2352-4642(23)00225-0.
439 Epub 2023 Oct 25. PMID: 37898144.
- 440 23. Boddington NL, Pearson I, Whitaker H, Mangtani P, Pebody RG. Effectiveness of influenza
441 vaccination in preventing hospitalization due to influenza in children: a systematic review and
442 meta-analysis. *Clin Infect Dis* 2021; 73: 1722–32.
- 443 24. Baum U, Kulathinal S, Auranen K, Nohynek H. Effectiveness of 2 influenza vaccines in
444 nationwide cohorts of Finnish 2-year-old children in the seasons 2015-2016 through 2017-2018.
445 *Clin Infect Dis* 2020; 71: e255–61.
- 446 25. Pebody R, Djennad A, Ellis J, et al. End of season influenza vaccine effectiveness in adults and
447 children in the United Kingdom in 2017/18. *Euro Surveill* 2019; 24: 1800488.
- 448 26. Cantarutti A, Gaquinto C. Pedianet database. In: Sturkenboom M, Schink T, editors. *Databases*
449 *for pharmacoepidemiological research. Springer series on epidemiology and public health.*
450 *Springer International Publishing* (2021). p. 159–64. doi: 10.1007/978-3-030-51455-6_13.
- 451 27. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated
452 gastroesophageal reflux disease in the first year of life with the subsequent development of
453 asthma. *Int J Environ Res Public Health.* 2021;18(18):9633.
- 454 28. Möst J, Redlberger-Fritz M, Weiss G. Multiple Influenza Virus Infections in 4 Consecutive
455 Epidemiological Seasons: A Retrospective Study in Children and Adolescents. *Open Forum*
456 *Infect Dis.* 2019 Apr 23;6(6):ofz195. doi: 10.1093/ofid/ofz195.
- 457 29. Batzella E, Cantarutti A, Caranci N, Giaquinto C, Barbiellini Amidei C, Canova C. The
458 Association Between Pediatric COVID-19 Vaccination and Socioeconomic Position: Nested
459 Case-Control Study From the Pedianet Veneto Cohort. *JMIR Public Health Surveill.* 2023 Feb
460 1;9:e44234. doi: 10.2196/44234. PMID: 36645419; PMCID: PMC9897308.
- 461 30. Newman, S.C. *Biostatistical Methods in Epidemiology; Wiley Series in Probability and*
462 *Statistics; John Wiley & Sons: Hoboken, NJ, USA, 2002.*
- 463 31. Sridhar S, Brokstad KA, Cox RJ. Influenza Vaccination Strategies: Comparing Inactivated and
464 Live Attenuated Influenza Vaccines. *Vaccines (Basel).* 2015 Apr 24;3(2):373-89. doi:
465 10.3390/vaccines3020373. PMID: 26343192; PMCID: PMC4494344.
- 466 32. Boddington NL, Mangtani P, Zhao H, et al. Live-attenuated influenza vaccine effectiveness
467 against hospitalization in children aged 2-6 years, the first three seasons of the childhood
468 influenza vaccination program in England, 2013/14-2015/16. *Influenza Other Respir Viruses*
469 2022; 16: 897–905.

- 470 33. Krishnan A, Dar L, Saha S, Narayan VV, Kumar R, Kumar R, Amarchand R, Dhakad S,
471 Chokker R, Choudekar A, Gopal G, Choudhary A, Potdar V, Chadha M, Lafond KE, Lindstrom
472 S, Widdowson MA, Jain S. Efficacy of live attenuated and inactivated influenza vaccines
473 among children in rural India: A 2-year, randomized, triple-blind, placebo-controlled trial. *PLoS*
474 *Med.* 2021 Apr 29;18(4):e1003609. doi: 10.1371/journal.pmed.1003609. PMID: 33914729;
475 PMID: PMC8118535.
- 476 34. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor
477 EM; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza
478 vaccine in infants and young children. *N Engl J Med.* 2007 Feb 15;356(7):685-96. doi:
479 10.1056/NEJMoa065368. Erratum in: *N Engl J Med.* 2007 Mar 22;356(12):1283. PMID:
480 17301299.
- 481 35. Marien AG, Hochart A, Lagrée M, Diallo D, Martinot A, Dubos F. Parental acceptance of an
482 intranasal vaccine: Example of influenza vaccine. *Arch Pediatr.* 2019 Feb;26(2):71-74. doi:
483 10.1016/j.arcped.2018.11.002. Epub 2019 Jan 15. PMID: 30658873.
- 484 36. Rodgers L, Pabst LJ, Chaves SS. Increasing uptake of live attenuated influenza vaccine among
485 children in the United States, 2008-2014. *Vaccine.* 2015 Jan 1;33(1):22-4. doi:
486 10.1016/j.vaccine.2014.11.006. Epub 2014 Nov 17. PMID: 25448098; PMID: PMC5845854.
- 487 37. Patel, M. M., York, I. A., Monto, A. S., Thompson, M. G., & Fry, A. M. (2021). Immune-
488 mediated attenuation of influenza illness after infection: opportunities and challenges. *The*
489 *Lancet. Microbe*, 2(12), e715–e725. [https://doi.org/10.1016/S2666-5247\(21\)00180-4](https://doi.org/10.1016/S2666-5247(21)00180-4)

490 ***Legend of Figures***

491 **Figure 1.** Flowchart of the study cohort. Pedianet dataset 2010-2024.

492

493 **Figure 2.** Monthly Administration Rates (AR) per 1,000 person-months of influenza vaccination
494 among children in Italy by vaccine type.

495


496 **Figure 3.** Comparison between LAIV-4 and IIV vaccine effectiveness in preventing influenza/ILI
497 in children in Italy.

498 **Table**

499 **Table 1.** Children sociodemographic and clinical characteristics by exposure.

	Unexposed (N = 125,142)	LAIV-4-exposed (N = 5,270)	IIV-exposed (N = 7,510)	P-value unexposed vs exposed (both LAIV-4 and IIV)*	P-value LAIV-4 vs. IIV*
Sex					
Male	64,439 (51.49%)	2,724 (51.69%)	3,937 (52.42%)	0.2866	0.4131
Female	60,703 (48.51%)	2,546 (48.31%)	3,573 (47.58%)		
Age				<.0001	<.0001
2-5 years	32,011 (25.58%)	3,034 (57.57%)	2,757 (36.71%)		
6-10 years	51,181 (40.90%)	1,754 (33.28%)	3,214 (42.80%)		
11-14 years	41,950 (33.52%)	482 (9.15%)	1,539 (20.49%)		
Region of birth in Italy				<.0001	<.0001
North	83,518 (66.74%)	2,067 (39.22%)	3,857 (51.36%)		
Center	18,546 (14.82%)	752 (14.27%)	1,752 (23.33%)		
South and islands	23,078 (18.44%)	2,451 (46.51%)	1,901 (25.31%)		
Deprivation index				<.0001	<.0001
Low	42,872 (34.26%)	1,949 (36.98%)	2,740 (36.48%)		
High	59,161 (47.28%)	2,720 (51.51%)	3,565 (47.47%)		
Missing	23,109 (18.47%)	601 (11.40%)	1,205 (16.05%)		
Comorbidity				<.0001	<.0001
None	119,922 (95.83%)	4,909 (93.15%)	6,772 (90.17%)		
At least one	5,220 (4.17%)	361 (6.85%)	738 (9.83%)		
Influenza vaccination status in the previous season				<.0001	<.0001
Unvaccinated	121,040 (96.72%)	2,026 (38.44%)	2,106 (28.04%)		
Vaccinated	4,102 (3.28%)	3,244 (61.65%)	5,404 (71.96%)		
Influenza/ILI episode(s) in the previous season				0.7772	0.4872
0	120,250 (96.09%)	5,058 (95.98%)	7,226 (96.22%)		
>=1	4,892 (3.91%)	212 (4.02%)	284 (3.78%)		
Drug prescription(s) in the previous season				<.0001	<.0001
0	91,634 (73.22%)	2,130 (40.42%)	4,306 (57.34%)		
1-2	26,039 (20.81%)	1,967 (37.32%)	2,259 (30.08%)		
>=3	7,469 (5.67%)	1,173 (22.26%)	945 (12.58%)		
Specialistic visit(s) in the previous season				<.0001	0.0011
0-7	106,415 (85.04%)	3,013 (57.17%)	4,510 (60.05%)		
>=8	18,727 (14.96%)	2,257 (42.83%)	3,000 (39.95%)		


500 * Chi-squared test.



¥ 9,309 children were excluded from the 2022/2023 cohort as they were only followed during the 2023/2024 influenza season and 31,114 children were excluded from the 2023/2024 cohort as they were only followed during the 2022/2023 influenza season

* PPIPs, Special Professional Commitment Services

** FP, family pediatrician



Type of vaccine	Influenza season	N of children		N of outcomes		HR (95% CI) *		Homogeneity test (p-value)
		Exposed	Unexposed	Exposed	Unexposed			
LAIV-4 IIV	2022/2024	5,270	125,142	154	6,212	0.57 (0.47 - 0.68)		0.095
		7,510	125,142	245	6,212	0.46 (0.39 - 0.54)		
LAIV-4 IIV	2022/2023	1,683	59,542	46	3,413	0.62 (0.44 - 0.88)		0.374
		4,320	59,542	172	3,413	0.51 (0.42 - 0.63)		
LAIV-4 IIV	2023/2024	3,587	65,600	108	2,799	0.60 (0.48 - 0.75)		0.048
		3,190	65,600	73	2,799	0.42 (0.32 - 0.56)		

* HRs were adjusted for sex, age at the start of each influenza season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the epidemiological season preceding the season of interest.